Lesson plan
3C-DFM
3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM). The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT 2 receptors and is known to act as an agonist of the serotonin 5-HT 2A and 5-HT 2B receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.
Article summary
3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM). The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT 2 receptors and is known to act as an agonist of the serotonin 5-HT 2A and 5-HT 2B receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.